A bipartisan group of lawmakers has urged the Food and Drug Administration to close a regulatory loophole regarding peptides. The STAT+ newsletter reports that FDA officials appear to be reviving a policy requiring drugs to be tested on their intended patient populations. This development follows a push by the legislative group to address gaps in current oversight. The report appears in the web edition of D.C. Diagnosis, a twice-weekly newsletter covering health and medicine policy. STAT+ subscribers can access the full story on this regulatory shift. The newsletter also highlights other upcoming events. Elevance Health holds its third-quarter earnings call on Wednesday. On Thursday, the KFF will release its annual Employer Health Benefits Survey, which offers insights into premiums, deductibles, and cost-sharing. Also on Thursday, a federal court will hear arguments in Commonwealth of Massachusetts v. Oz. This lawsuit was brought by 25 states and D.C. challenging the Trump administration's implementation of new Medicaid work requirements. The newsletter invites readers to send news tips and boring truths about liars to John Wilkerson via email or Signal.